TDO2 Inhibitors

US10800780B2 · kind B2 · utility

Assignees

• Genentech, Inc. · US
• NEWLINK GENETICS CORPORATION · US

Inventors

• Xingyu Lin · Beijing, CN
• Po-Wai Yuen · Ann Arbor, US
• Rohan Mendonca · South San Francisco, US
• Brendan Parr · South San Francisco, US
• Richard Pastor · South San Francisco, US
• Zhonghua Pei · South San Francisco, US
• Lewis Gazzard · Belmont, US
• Firoz Jaipuri · Bengaluru, IN
• Sanjeev Kumar · Ann Arbor, US
• Xiaokai Li · Middleton, US
• Roheeth Pavana · Ames, US
• Hima Potturi · Ames, US
• Venkata Velvadapu · Ankeny, US
• Jesse Waldo · Huxley, US
• Zuhui Zhang · Ames, US
• Guosheng Wu · Beijing, CN
• Benjamin Sellers · Larkspur, US

Key dates

• Filing date: Dec 23, 2016
• Grant date: Oct 13, 2020
• Expiry date: Dec 23, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2300/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.